PRLog (Press Release)
- Oct. 29, 2013 - CENTRAL LONDON, U.K. --
The report shows a main driver for growth in the industry will be anti-smoking legislation across much of the world, even in countries with social acceptance of tobacco smoking. In addition, the work found there is a general trend in expanding access to smoking cessation products in public healthcare systems. These reasons will increase the market for anti-smoking medicines. Visiongain’s analysis also found that within Europe, the UK and Spanish markets will be the main drivers of growth. Among the BRIC nations, the study expects the Brazilian market to show the strongest revenue growth, mainly owing to strengthening of legislation and higher taxes on cigarettes.
Hamza Baig, a pharmaceutical (http://www.visiongain.com/Sector/8/Pharma
) industry analyst in visiongain, said: “The global smoking cessation market will show robust growth over the next few years, despite difficult economic conditions. My analysis found nicotine replacement therapies (NRTs) and nicotine receptor partial agonists (NRPAs) will show the most sales expansion. The expected launch of Tabex, an NRPA, in developed world markets over the next few years will be a major driver for sales growth in the industry as a whole, owing to safety, ease of use and lower cost.
“Moreover, my research found there is a high attrition in the R&D pipeline. For products under development that do not reach the market, there do not yet appear to be enough replacement candidates.”
That new study shows revenue forecasts to 2023 at overall world market, submarket, product and national level. It forecasts these world-level submarkets:
Over-the-counter medicines (OTC)
Prescription drugs (Rx)
Nicotine replacement therapies (NRT)
Nicotine receptor partial agonists (NRPA)
The new work also analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC), with revenue forecasts to 2023. That study also forecasts sales of leading products and assesses research and development (R&D). The work includes four interviews, three with companies, and other qualitative analyses of the industry.
Smoking Cessation Drugs: World Market Prospects 2013-2023 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For more information of this report please click on http://www.visiongain.com/Report/1118/Smoking-Cessation-D...
or email Sara Peerun on sara.peerun@